News

Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

Vienna (Austria), 6 November 2017 – Themis today announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, the Company`s live attenuated prophylactic vaccine candidate for chikungunya fever.

The data will be presented today for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA.

Final results of the trial in 320 healthy subjects currently ongoing in Austria and Germany are expected in 2018.

“The data we have generated so far in our clinical development program for chikungunya are very encouraging. All currently active phase 2 trials including a study in a previously epidemic area are progressing well and we expect final results in 2018 and 2019, respectively to further increase the value proposition of our product candidate. Overall, Themis continues to lead in the development of a vaccine against chikungunya,“ commented Dr. Erich Tauber, CEO and founder of Themis. “Above and beyond chikungunya, the trial results further validate our technology platform, which has the potential to become the leading source for innovative vaccines against several emerging and established infectious diseases.”

Themis’ unique technology platform is based on a measles vaccine vector that can be easily modified genetically in a “plug-and play” fashion to express a variety of selected antigen proteins that are present in infectious pathogens. The Company’s product portfolio based on this platform includes clinical product candidates in chikungunya and Zika with additional preclinical candidates in Respiratory Syncytial Virus (RSV), norovirus and Cytomegalovirus (CMV).

About Themis:

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.

About Chikungunya

Chikungunya fever is a viral infection transmitted by specific mosquitoes. It originates in Africa but the increase in global traveling and rising temperatures cause these mosquitoes and the viruses they carry to spread into more temperate zones. Within the last four years, well over 1.7 million cases have been reported from 45 countries in the Americas and the Caribbean alone. The majority of infected persons develop severe joint pain, which can become chronic.

For more information please contact:

Themis

Dr. Erich Tauber

CEO

Phone: +43 / 1 / 236 7151

[YjY0dGFnOmVyaWNoLnRhdWJlckB0aGVtaXNiaW8uY29t]

Media requests:

MacDougall Biomedical Communications

Mario Brkulj or Dr. Jacob Verghese

Phone: +49 89 2420 9345 or +49 89 2420 9346

[YjY0dGFnOm1icmt1bGpAbWFjYmlvY29tLmNvbQ==]

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

more

Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

more

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine

more

Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

more

Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine. Themis Measles Vector Technology Central to Action Plan

more

Themis Bioscience Successfully Closes 10 M EUR Financing Round

more

Zika Vaccine Development Receives Big Boost by Innovate UK

more

Interview W24/Zika

more

New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority.

more

New Horizons For Measles-Based Vaccines And Therapies

more

Two renowned Vaccine Experts Joining Themis Bioscience GmbH

more

Themis Bioscience’s Raises up to EUR 10 Million in Series B New Board to drive partnerships and commercialization of product pipeline

more